Mark Copley, Sales Director for Copley Scientific, will use his invited presentation opportunity at the Indian Pharmaceutical Association’s (IPA) 6 th symposium on nasal and pulmonary drug delivery (24-25th October 2013, Mumbai) to discuss bioequivalence testing for inhaled generics. Copley Scientific is also a gold sponsor for the event which this year will focus on global regulatory trends in inhaled product testing and development. To find out more or to register please visit www.ipapharma.org
The Indian pharmaceutical industry is a global leader in the development of generic inhaled products, primarily for the treatment of chronic obstructive pulmonary diseases (COPD) and asthma. Demonstrating bioequivalence through in vitro testing minimises the need for clinical trials, accelerating time to market and reducing development costs. In a presentation, entitled “Methodologies for in vitro bioequivalence testing of generic inhaled products in emerging markets”, Mr Copley will review the regulatory framework in this area and outline efficient testing strategies that can be used to fulfil the associated requirements.
Copley Scientific is the world’s leading manufacturer and supplier of inhaler test equipment with a track record of innovating new products to meet evolving requirements for both novel and generic inhaled product testing. Solutions of particular value for generic testing include a range of equipment for delivered dose uniformity and aerodynamic particle size measurement, cost-efficient breathing simulators for nebuliser testing, and unique instruments such as the Plume Temperature Tester Model PTT 1000 for measurement of the Cold Freon effect. In combination with Copley Scientific’s expert support these products help generics manufacturers to fully meet regulatory requirements and bring new products to market quickly and efficiently.
Ends
Mark Copley, Sales Director for Copley Scientific, will be presenting on bioequivalence testing for generics at 6th IPA symposium
About Copley Scientific
Copley Scientific is recognised as the world’s leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company is also active in detergent testing, air sampling and aerosol characterisation.
Copley Scientific’s pharmaceutical product range includes test equipment for: delivered dose uniformity and aerodynamic particle size measurement of metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays; as well as tablets (dissolution, disintegration, friability and hardness) capsules, powders, suppositories and transdermals.
Copley Scientific has offices in the UK and Switzerland. The company works in partnership with aerosol particle science experts MSP Corporation in North America, and also distributes MSP Corporation’s air sampling and aerosol characterisation products throughout Europe.
Serving the pharmaceutical and associated industries, Copley Scientific offers an extensive range of equipment for research, development and quality control, as well as full validation and aftersales services. This broad range of products is supplied and supported worldwide through a network of specialist distributors. www.copleyscientific.com
